The PBM Rebate Math That Turns Prior Auths Into a Pharma Negotiating Tool

What if a prior authorization has less to do with your medical need than with how big a rebate check a PBM is collecting on a competing drug? In this solo deep dive — a direct follow-up to last week's conversation with Ophelia Johnson on GLP-1s and cash pay (EP516 link below) — host Stacey Richter walks through a "Brand Darling" vs. "Brand 2" case study showing how PBM/GPO rebate contracting and the Inflation Reduction Act's pressure on list prices can turn prior auths and step therapy into negotiating leverage rather than clinical guardrails. She also breaks down the GoodRx reverse-auction mechanic and why a growing number of pharma manufacturers are responding to rebate-driven formulary exclusion by going cash-pay direct to patients.

WHAT YOU'LL LEARN

✅ How PBM/GPO rebate contracts create a "rebate cliff" that locks new or lower-cost drugs out of formulary, regardless of price or clinical efficacy

✅ Why prior authorizations and step therapy are often used as a financial negotiating lever to extract bigger rebates from a dominant "Brand Darling," rather than as a clinical-necessity check

✅ How the Inflation Reduction Act's list-price pressure is collapsing the rebate spread that funds the current PBM contracting model

✅ Why cash-pay and direct-to-patient strategies are becoming a more attractive option for pharma brands excluded from preferred formulary tiers

✅ How GoodRx's reverse-auction model actually generates its advertised cash prices, and how GoodRx profits from sponsored placement, copay-card integration, and data sales

✅ Why copay accumulators and maximizers can erase the value of a manufacturer's copay card even when a patient does get coverage

WHY THIS MATTERS

For self-insured employers and plan sponsors footing the bill, this episode is a reminder that a prior authorization or a formulary tier placement may be a financial calculation between a PBM and a manufacturer first, and a clinical determination second. Because coinsurance is calculated off an inflated list price, the same rebate-cliff dynamics that lock a lower-cost drug out of formulary can also push more cost directly onto plan members. And as the Inflation Reduction Act squeezes the rebate spread that funds this model, cash-pay and direct-to-patient strategies are emerging as an alternative worth watching — even though, as Stacey notes, the usual PBM players are often still involved behind the scenes.

MENTIONED IN THIS EPISODE

EP516 with Ophelia Johnson: Apple Podcasts | Spotify | Other Apps

Post by Robyn Tikia

AEE13 with Ge Bai, PhD, CPA: Apple Podcasts | Spotify | Other Apps

=== LINKS ===

🔗 Show Notes with all mentioned links: Show Notes

✉️ Enjoy this podcast? Subscribe to the free weekly newsletter

🫙 Support the podcast with a small donation to the Tip Jar

🎤 Follow us on Apple Podcasts

🎤 Follow us on Spotify

📺 Subscribe to our YouTube channel

=== CONNECT WITH THE RHV TEAM ===

✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X

00:00 Introduction to this episode.

03:53 What needs to be true, no matter what your pharma brand is.

04:20 Why a PBM picks a brand "darling."

05:10 A message to PBM sales teams.

09:43 Clarifying a point about formulary decision making.

14:34 When might a cash-pay strategy start to look rational for a pharma brand?

16:25 Cash pay versus formulary from the patient perspective.

19:50 How PBMs feel about brands going cash pay.

20:56 Why GoodRx is allowed to sell non-formulary Rxs at cash prices on PBMs.

23:51 A clarification of points on GoodRx.

26:19 A point to ponder about discount coupons.